Clinical Trial Update: An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa [Phase 3]

View source ↗

Summary

An open-label extension safety study of SD-101 for Epidermolysis Bullosa is planned (Phase 3) and currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa

Drugs mentioned

• SD-101

Snippet

Sponsor: Paradigm Therapeutics | Conditions: Epidermolysis Bullosa (EB) | Phase 3 | Status: NOT_YET_RECRUITING